产品
编 号：F752996
分子式：C25H29NO3S2
分子量：455.63
分子式：C25H29NO3S2
分子量：455.63
产品类型
规格
价格
是否有货
结构图
CAS No: 2460738-32-1
产品详情
生物活性：
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity.
体内研究：
CT1-3 (20 mg/kg; IP, for 28 days) significantly suppresses tumor growth and exhibits no hepatic and renal toxicity in MDA-MB-231 xenografts model.Animal Model:Male BALB/c-nu/nu mice (injected with A549, OVCAR3 and MDA-MB-231)
Dosage:20 mg/kg
Administration:IP, for 28 days
Result:Significantly suppresses tumor growth and exhibited no hepatic and renal toxicity.
体外研究：
CT1-3 has excellent inhibitory activity against multiple cancer cells with IC50 range of 5.10~14.06 μM in LOVO, A549, HepG2, MDA-MB-231 and HONE1, et al.CT1-3 (10 μM; 24 h) notably increases ROS production in HCCs, significantly decreases mitochondrial membrane potential, and reduces Bcl-2 and XIAP levels and increases phospho-JNK and Bax levels.CT1-3 (7.5 μM; 24 h) reduces the capacity of migration and invasion of HCCs, significantly promotes the expression level of E-cadherin (E-cad), and markedly decreases the pro-metastatic and pro-invasive protein Snail.
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity.
体内研究：
CT1-3 (20 mg/kg; IP, for 28 days) significantly suppresses tumor growth and exhibits no hepatic and renal toxicity in MDA-MB-231 xenografts model.Animal Model:Male BALB/c-nu/nu mice (injected with A549, OVCAR3 and MDA-MB-231)
Dosage:20 mg/kg
Administration:IP, for 28 days
Result:Significantly suppresses tumor growth and exhibited no hepatic and renal toxicity.
体外研究：
CT1-3 has excellent inhibitory activity against multiple cancer cells with IC50 range of 5.10~14.06 μM in LOVO, A549, HepG2, MDA-MB-231 and HONE1, et al.CT1-3 (10 μM; 24 h) notably increases ROS production in HCCs, significantly decreases mitochondrial membrane potential, and reduces Bcl-2 and XIAP levels and increases phospho-JNK and Bax levels.CT1-3 (7.5 μM; 24 h) reduces the capacity of migration and invasion of HCCs, significantly promotes the expression level of E-cadherin (E-cad), and markedly decreases the pro-metastatic and pro-invasive protein Snail.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备